SCHEMBL16632676

SCHEMBL16632676

Cc1ccc2c(Oc3ccccc3O)cccc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.49
PLAU P00749 1/20 0.42
CYP2A6 P11509 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
HSD17B1 P14061 1/20 0.41
HSD17B2 P37059 1/20 0.41
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
TP53 P04637 1/20 0.40
TSHR P16473 1/20 0.40
KDM4E B2RXH2 1/20 0.39
KMT2A Q03164 4/20 0.39
POLB P06746 3/20 0.39
GAA P10253 2/20 0.39
MEN1 O00255 2/20 0.38
ESR1 P03372 1/20 0.38
ESR2 Q92731 1/20 0.38
ALDH1A1 P00352 1/20 0.38
RAB9A P51151 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13871406 0.88 CYP1A2 (0.61) CYP1A2CYP2A6TDP1KDM4EGAA
SCHEMBL16632732 0.82 CYP1A2 (0.50) CYP1A2CYP2A6TDP1CA1CA2
SCHEMBL676533 0.81 CYP1A2 (0.58) CYP1A2TDP1CA1CA2TP53
SCHEMBL16632629 0.81 TTR (0.45) PLAUCYP2A6HSD17B1HSD17B2KMT2A
SCHEMBL13871403 0.80 CYP1A2 (0.52) CYP1A2CYP2A6TDP1KDM4EGAA
SCHEMBL16920391 0.80 CYP1A2 (0.52) CYP1A2CYP2A6TDP1KMT2APOLB
SCHEMBL7546534 0.79 CA1 (0.48) CA1CA2TP53TSHRGAA
SCHEMBL773863 0.79 CYP1A2 (0.63) CYP1A2PLAUCYP2A6TDP1HSD17B1
SCHEMBL16640616 0.78 AR (0.43) CYP1A2CA1CA2KMT2AMEN1
SCHEMBL16632510 0.77 CA1 (0.46) PLAUCA1CA2KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9382245-B2 Compounds and methods for treating HIV infections YALE UNIVERSITY (US) 2016-07-05 US disclosed
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS POLM, POLRMT, DHFR CYP1A2 567/4885PLAU 2393/4885CYP2A6 785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.